CTIS2022-502024-51-00进行中（未招募）1 期
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg. - LR-302
Chemo Research S.L.0 个研究点目标入组 1,356 人开始时间: 2023年3月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,356
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •[Visit 1a:] Sexually active, postmenarcheal and premenopausal female subjects = 18 years at risk of pregnancy including breastfeeding women., [Visit 1a:] Agree not to participate in any other clinical trials during the course of this trial (participation in a non-interventional study is allowed)., [Visit 1a:] Women who either a. have never used hormonal contraceptives before consent (naïve users), or b. have used hormonal contraceptives in the past, but have had a hormonal contraceptive-free period before consent and a full menstrual cycle during the drug-free period (previous users) or c. directly switch from another hormonal contraceptive (switchers)., [Visit 1a:] Only for subjects who were not pregnant and did not use hormonal contraception during the last 6 months before consent: Regular cycles (i.e. cycle length between 24 and 35 days) during the last 6 months., [Visit 1a:] Only for women who were pregnant within the last 6 months before consent: At least 3 complete menstrual cycles after pregnancy. Breastfeeding women can be included 4 weeks after delivery irrespective of menstrual cycles post-delivery., [Visit 1a:] Systolic blood pressure = 140 mm Hg and diastolic blood pressure = 90 mm Hg, subjects with controlled hypertension are allowed., [Visit 1a:] A written informed consent is available, prior to undergoing any trial-related procedure., [Visit 1a:] Willing to use the trial contraception they were randomised to (vaginal ring or oral tablet) for nine 28-day cycles., [Visit 1a:] Be willing to have intercourse in each cycle of the trial without the need to use back-up contraceptive., [Visit 1a:] Be willing to state that, to her best knowledge, her male sexual partner/partners has/have not had a vasectomy or been previously diagnosed as infertile.
排除标准
- •[Visit 1a / Visit 1b:] Pregnancy or wish of pregnancy., [Visit 1a:] Severe COVID-19 disease or less than 3 months after hospitalization due to a COVID-19 disease., [Visit 1a:] Known HIV infection., [Visit 1a:] Known current or chronic hepatitis B or C., [Visit 1a:] Gastrointestinal (malabsorptive) disease including inflammatory bowel disease (Crohn's disease or ulcerative colitis), gastric bypass surgery, current post gastrectomy syndrome and celiac disease., [Visit 1a / Visit 1b:] Prohibited previous medication/therapy (as given in the protocol), [Visit 1a / Visit 1b:] Dependence on prohibited co-medication/-therapy (as given in the protocol), [Visit 1a / Visit 1b:] Progestin-releasing intra-uterine device (IUD) or contraceptive implant received or in place within the last 2 months., [Visit 1a:] Planned regular concomitant use of barrier contraceptive methods, spermicides, IUDs or other contraceptive measures., [Visit 1a:] Subject is a member of the investigator’s or sponsor’s staff or a relative or family member thereof., [Visit 1a:] Is in custody or submitted to an institution by a court order., [Visit 1a:] Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary., [Visit 1a / Visit 1b:] Any condition or any disease that, in the opinion of the investigator, may jeopardize protocol compliance or the scientific integrity of the trial., [Visit 1a:] History of infertility., [Visit 1a:] Known bleeding disorder or history of unexplained bleeding or bruising within the last 12 months prior to V1a., [Visit 1a:] Unexplained amenorrhea., [Visit 1a:] Abnormal finding on pelvic, breast or ultrasound examination that in the investigator’s opinion contraindicates participation in the trial., [Visit 1a:] Women - with a Papanicolaou (Pap) smear reading low-grade squamous intraepithelial lesion (LGSIL) or higher at screening. Subjects with atypical squamous cells of undetermined significance (ASC-US) can be included if they are negative for high-risk human papilloma virus (HPV) strains., [Visit 1a:] Known contraindication including: a. Active venous thromboembolic disorder and/or a VTE history including a known positive family history in a sibling or parent. b. Arterial and cardiovascular disease, past or present (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease). c. Major surgery with prolonged immobilisation. d. Diabetes mellitus with vascular involvement. e. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. f. Presence or history of liver tumours (benign or malignant). g. Known severe renal insufficiency or acute renal failure. h. Known adrenal insufficiency. i. Known or suspected sex steroid sensitive malignancies, including breast cancer. j. Hypersensitivity to the active substance, soya, peanut or to any of the excipients. k. Hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption., [Visit 1a:] Uncontrolled concomitant chronic diseases (i.e., not on a stable treatment dose for at least 2 months at the time of consent).
研究者
相似试验
终止
3 期
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) TrialACTRN12613000243718Acute Stroke Service680
已完成
不适用
Recurrent cutaneous squamous cell carcinoma under Rapamune®Squamous cell carcinoma (SCC)CarcinomaCancerISRCTN98226084Wyeth Pharmaceuticals B.V. (The Netherlands)180
进行中（未招募）
不适用
An open-label, randomized, multicenter, clinical study to comparethe effects of telithromycin, azithromycin and cefuroxime axetilon the penicillin or macrolide resistance of Streptococcus pneumoniaein patients with acute exacerbation of chronic bronchitis - PerspectiveEUCTR2004-001412-30-HUaboratoire Aventis5,660
进行中（未招募）
不适用
A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects with type 2 diabetes inadequately controlled on basal insulin with or without oral anti-diabetic drugs: Step-wise addition versus complete basal-bolus therapy - Full STEP™MedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2010-018974-19-SIovo Nordisk A/S848
进行中（未招募）
1 期
A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects with type 2 diabetes inadequately controlled on basal insulin with or without oral anti-diabetic drugs: Step-wise addition versus complete basal-bolus therapy - Full STEP™MedDRA version: 12.1Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusType 2 DiabetesEUCTR2010-018974-19-FRovo Nordisk A/S